Blue Trust Inc. Has $76,000 Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Blue Trust Inc. lifted its position in Ascendis Pharma A/S (NASDAQ:ASND) by 540.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 506 shares of the biotechnology company’s stock after purchasing an additional 427 shares during the quarter. Blue Trust Inc.’s holdings in Ascendis Pharma A/S were worth $76,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Wilmington Savings Fund Society FSB acquired a new stake in shares of Ascendis Pharma A/S in the third quarter valued at $30,000. Groupama Asset Managment acquired a new position in shares of Ascendis Pharma A/S during the third quarter valued at $60,000. GAMMA Investing LLC boosted its holdings in Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 214 shares during the last quarter. Signaturefd LLC increased its position in Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 80 shares during the period. Finally, Pursue Wealth Partners LLC bought a new stake in Ascendis Pharma A/S during the 3rd quarter worth about $217,000.

Wall Street Analysts Forecast Growth

ASND has been the subject of a number of analyst reports. TD Cowen lowered their target price on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a report on Friday, November 15th. Cantor Fitzgerald restated an “overweight” rating and issued a $170.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. UBS Group assumed coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They set a “buy” rating and a $196.00 price objective on the stock. Wedbush reissued an “outperform” rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Finally, JPMorgan Chase & Co. raised their price target on Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $191.57.

Ascendis Pharma A/S Stock Performance

NASDAQ:ASND opened at $120.87 on Friday. The stock’s 50-day simple moving average is $132.60 and its 200 day simple moving average is $132.49. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $161.00. The company has a market cap of $7.34 billion, a P/E ratio of -14.96 and a beta of 0.64.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.